Loading...

HUMA - Humacyte, Inc.

Analyst Downgrade Signal for 05-16-2022
Analyst Downgrade Signal: HUMA from Overweight to Underweight by Piper Sandler
Price Target: $10>>4


Loading Chart HUMA

Stock Signal Information


Signal

Analyst Downgrade Signal: HUMA from Overweight to Underweight by Piper Sandler
Price Target: $10>>4
Report Date: 05-16-2022
Symbol: HUMA - Humacyte, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Downgrade Signal: HUMA from Overweight to Underweight by Piper Sandler
Price Target: $10>>4

  HUMA Technical Analysis

Company Contact

Humacyte, Inc. (HUMA)
2525 E. NC Highway 54
Durham, NC
Phone: 919 313 9633
Website: http://www.humacyte.com
CEO:

HUMA, Humacyte, Inc.

HUMA Humacyte, Inc. Logo Image

NASDAQ, NasdaqGS


Company Profile

Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded in 2004 and is based in Durham, North Carolina.